Close

CellRapeutics™ CAR-Treg Development

Creative Biolabs is a cellular immunotherapy company dedicated to the development of innovative T cell therapies for the treatment of diseases with a high unmet medical need. Benefiting from our expertise in CAR-T cell development, we are able to harness science and technology to create CAR-Tregs products that support the next generation of cell therapy innovation.

Challenges for Conventional CAR-T Cell

CAR-T cell therapy has shown remarkable efficacy in the treatment of liquid tumors such as acute leukemia and non-Hodgkin's lymphoma, and is therefore considered to be one of the most promising cell-based immunotherapies. However, until recently, the use of CAR T cell therapy was limited to small clinical trials, primarily because these therapies caused a variety of worrying, sometimes fatal side effects in some patients. The most common one is the cytokine release syndrome (CRS). In addition, evidence suggests that CAR-T cells are targeted to activate antigens expressed on T cells, which are transformed into inducible Treg cells as tumor metastasis progresses. Therefore, the innovative CAR cell therapy targeting Treg has attracted the attention of researchers and the public.

Advantages of CAR-Treg Cells

Cellular therapies using polyclonal regulatory T cells (Tregs) in transplantation and autoimmune diseases have been performed in both animal models and clinical trials. However, polyclonal Tregs cause adverse reactions, such as systemic immunosuppression, since a large number of cells are of unknown antigen specificity. This can be avoided by utilizing antigen-specific Tregs, that is, by transfecting the viral vector encoding the chimeric antigen receptor (CAR) of a specific antigen into Treg to achieve precise modification. Recognized advantages include:

  • CAR-Tregs is superior to polyclonal Tregs in antigen inhibition.
  • CAR-Tregs has a stable phenotype and function and tends to migrate to target organs associated with disease for maximum inhibition.
  • CAR-Tregs mediated inhibition is antigen specific, which may result in fewer side effects associated with general immunosuppression.
  • Compared with TCR-Treg, CAR-Treg is not restricted by MHC and is less dependent on IL-2.

Schematic representation the structure of CAR-modified regulatory T cells (CAR-Tregs).

Fig.1 Schematic representation the structure of CAR-modified regulatory T cells (CAR-Tregs). (Zhang, 2018)

One-stop CAR-Treg Therapy Development

CellRapeutics™ CAR-Treg Development

For more detailed information, please feel free to contact us or directly sent us an inquiry.

Reference

  1. Zhang QF.; et al. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Front. Immunol. 2018.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.